NCT03691714 2023-12-08Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaUniversity of CincinnatiPhase 2 Unknown36 enrolled
NCT03799744 2022-03-28Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell CarcinomaInstitut Català d'OncologiaPhase 1 Unknown20 enrolled
NCT02658214 2020-08-20Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid TumorsAstraZenecaPhase 1 Completed32 enrolled